Whitney J. Palmer

Patients with severe psoriasis are also at a significant increase for developing advanced liver fibrosis, new research shows

Women who have primary Sjögren’s Syndrome also have decreased lifetime exposure to estrogen, a new study has determined.

EULAR has issued new treatment guidelines for antiphospholipid syndrome, a disorder of the immune system that causes blood clots. Among the recommendations, high risk individuals who carry the antiphospholipid antibody should take low-dose aspirin, even if they are asymptomatic. This also applies to systemic lupus erythematosus patients and women with a history of obstetric antiphospholipid syndrome.

Rheumatoid arthritis patients who failed first-line methotrexate achieved better outcomes with upadacitinib monotherapy, shows a new clinical trials report.

Rheumatoid arthritis patients treated with baricitinib at any point during their treatment, experience improved outcomes, a new clinical trials report shows.

Women who have primary Sjögren’s Syndrome also have decreased lifetime exposure to estrogen, a new study finds.

Children born to women who have rheumatoid arthritis during pregnancy could experience life-long health effects due to changes to DNA that alter genetic activity, new research indicates.

Sjögren’s Syndrome affects American Indians at a higher rather rate than other ethnic groups, but the lack of classically-associated disease symptoms makes diagnosis difficult, new research shows.

The questions patients ask sometimes differ from the questions doctors want them to ask, find researchers reporting in Arthritis Care & Research. In this slideshow, we compare the top five questions patients ask after an osteoarthritis diagnosis to the top five questions doctors had in mind.

Patients with systemic lupus erythematosus (SLE) are at an increased risk for fractures, new research shows. The risk is particularly high among patients with lupus nephritis.

Fatigue in patients with systemic lupus erythematosus (SLE) has been linked to anti-NR2 antibodies, which responds to treatment with belimumab, a study shows.

Lutikizumab does not improve pain or imaging outcomes for patients with erosive hand osteoarthritis, according to new research.

While gout does not increase the risk of death post-acute coronary syndrome, a new study shows the condition does increase an individual’s risk for readmission after heart failure, as well as the number of days he or she will spend on the hospital.

Patients with systemic sclerosis-associated interstitial lung disease who also take nintedanib experience a lower drop in their forced vital capacity, according to a new study.

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

Despite being the most common form of inflammatory arthritis, gout continues to be poorly managed, new research indicates.

Obese patients with osteoarthritis who take metformin have a slower rate of medial cartilage loss, putting them at a reduced risk for total knee replacement, a new study found.

Racial and ethnic minority patients with lupus develop more kidney, neurological, and blood manifestations than their white counterparts, according to new research.

Despite recommendations against using opioids and benzodiazepines to treat osteoarthritis pain, new research shows significant numbers of patients, especially older patients, are still receiving prescriptions for these medications.

Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results.

Getting more exercise can reduce a woman’s risk of developing rheumatoid arthritis, according to new research.

From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.

Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows.

Glucocorticoids are highly effective in treating inflammatory conditions. However, these medications also pose a significant risk for bone loss and fracture. In this slideshow, we cover the treatment guidelines.

To help clinicians manage antirheumatic drug therapy, the ACR and the American Association of Hip and Knee Surgeons developed evidence-based guidelines for the perioperative management of antirheumatic medication for patients with rheumatic diseases undergoing knee or hip surgery. In this slideshow, we outline those recommendations.

The JAK inhibitor tofacitinib presents a comparably low risk of venous thromboembolism to rheumatoid arthritis patients as do TNFi inhibitors, according to a new study.

Tofacitinib 5 mg or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows.

Baricitinib treatment does not increase the risk for cardiovascular problems in patients with rheumatoid arthritis, according to new research.

Rheumatoid arthritis patients taking tofacitinib could face some increased risks for significant cardiovascular events, depending upon their underlying characteristics, according to the results of a new study.

Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.